If you click “Continue” below, you will leave the current site and be taken to a site maintained by a third party that is solely responsible for its content. Amgen provides this link as a service to website visitors. Amgen is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Knowing your patients’ LDL-C helps you quickly identify their risk of having a CV event, adherence to lifestyle modifications, and effectiveness of treatment.
Frequent LDL-C testing is recommended by the 2018 AHA/ACC/Multi-society guideline1
* To assess adherence and response to change in lifestyle or LDL-C lowering therapy.
Fewer than 1 in 4 patients with ASCVD who are at very high risk have their LDL-C tested after a recent myocardial infarction. Risk of another CV event is higher in patients with prior myocardial infarction than those without. LDL-C testing can reveal if there are issues with adherence to lifestyle recommendations or treatment.
Retrospective study using the IQVIA (Longitudinal Access and Adjudication data; LAAD)
database of patients (N = 16,406,925) with ASCVD at very high risk who had a heart attack (January 2018 to December 2022).
VHR = very high risk.
† Terms and conditions apply. Programs subject to change; quantities may be limited. For details, visit: www.attackheartdisease.com/free-ldl-c-test.
AHA/ACC = American Heart Association/American College of Cardiology; ASCVD = atherosclerotic cardiovascular disease; ECDP = Expert Consensus Decision Pathway; LAAD = Longitudinal Access and Adjudication Data.